STOCK TITAN

TG Therapeutics (TGTX) director awarded 8,325 Stock Tracking Units in Form 4 filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

HUME DANIEL reported acquisition or exercise transactions in this Form 4 filing.

TG Therapeutics director Daniel Hume reported a compensation grant of 8,325 Stock Tracking Units (STUs). Each STU is a contingent right to receive either one share of common stock or a cash payment equal to the fair market value of one share, no later than 30 days after the first anniversary of the grant date. The STUs vest on the first anniversary only if he remains in continuous service with the company, and he now holds 8,325 STUs directly.

Positive

  • None.

Negative

  • None.
Insider HUME DANIEL
Role null
Type Security Shares Price Value
Grant/Award Stock Tracking Unit 8,325 $0.00 --
Holdings After Transaction: Stock Tracking Unit — 8,325 shares (Direct, null)
Footnotes (1)
  1. Each stock tracking unit ("STU") represents a contingent right to receive either (determined at the sole discretion of the committee of the Board of Directors of the Issuer that administers the Issuer's 2022 Incentive Plan) (i) one share of the Issuer's common stock or (ii) a cash payment equal to the fair market value of one share of the Issuer's common stock, no later than thirty (30) days after the first anniversary of the date of grant. Provided the Reporting Person remains in continuous service with the Issuer through the vesting date, the STUs shall vest upon the first anniversary of the date of grant.
Stock Tracking Units granted 8,325 units Grant of Stock Tracking Units on June 11, 2026
Total STUs after transaction 8,325 units Holdings following reported grant
Underlying common stock per STU 1 share Each STU represents right tied to one common share
Settlement window 30 days Settlement no later than 30 days after first anniversary
Vesting period 1 year Vest on first anniversary of grant if service continues
Stock Tracking Unit financial
"Each stock tracking unit ("STU") represents a contingent right to receive either..."
contingent right financial
"represents a contingent right to receive either (i) one share... or (ii) a cash payment..."
fair market value financial
"a cash payment equal to the fair market value of one share of the Issuer's common stock"
The price a willing buyer and a willing seller would agree on for an asset or security when neither is under pressure and both have access to the same information. Think of it as the market’s neutral estimate of what something is worth, like the price two neighbors would settle on for a car after comparing similar listings. Investors care because fair market value guides buying and selling decisions, tax reporting, portfolio valuation, and how accurately company assets are reflected in financial statements.
vesting financial
"the STUs shall vest upon the first anniversary of the date of grant"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
2022 Incentive Plan financial
"the committee of the Board of Directors... that administers the Issuer's 2022 Incentive Plan"
A 2022 incentive plan is a formal program adopted in 2022 that outlines how a company will reward employees, executives, or directors with cash, stock, or other benefits tied to performance or continued service. Investors care because these plans can change how much ownership exists (dilution), affect reported profits through compensation costs, and influence whether managers are motivated to increase long‑term value—think of it as the rules for a company’s bonus and stock‑award system.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
HUME DANIEL

(Last)(First)(Middle)
3020 CARRINGTON MILL BLVD, SUITE 475

(Street)
MORRISVILLE NORTH CAROLINA 27560

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
TG THERAPEUTICS, INC. [ TGTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Tracking Unit(1)06/11/2026A8,325 (2) (2)Common Stock8,325$08,325D
Explanation of Responses:
1. Each stock tracking unit ("STU") represents a contingent right to receive either (determined at the sole discretion of the committee of the Board of Directors of the Issuer that administers the Issuer's 2022 Incentive Plan) (i) one share of the Issuer's common stock or (ii) a cash payment equal to the fair market value of one share of the Issuer's common stock, no later than thirty (30) days after the first anniversary of the date of grant.
2. Provided the Reporting Person remains in continuous service with the Issuer through the vesting date, the STUs shall vest upon the first anniversary of the date of grant.
/s/ Daniel Hume06/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did TG Therapeutics (TGTX) director Daniel Hume report?

Daniel Hume reported receiving 8,325 Stock Tracking Units as compensation. These derivative awards give him future rights tied to TG Therapeutics common stock value, rather than reflecting an open-market share purchase or sale.

What is a Stock Tracking Unit (STU) in the TG Therapeutics (TGTX) Form 4?

Each Stock Tracking Unit is a contingent right to receive either one TG Therapeutics common share or a cash payment equal to one share’s fair market value. Settlement occurs within 30 days after the first anniversary of the grant date.

When do Daniel Hume’s TG Therapeutics (TGTX) Stock Tracking Units vest?

The 8,325 Stock Tracking Units vest on the first anniversary of the grant date. Vesting is conditioned on Hume remaining in continuous service with TG Therapeutics through that vesting date, according to the incentive plan terms.

Does the TG Therapeutics (TGTX) Form 4 show Daniel Hume buying or selling stock?

The filing shows a grant of 8,325 Stock Tracking Units, not an open-market stock purchase or sale. It is a compensation-related derivative award rather than a discretionary trade in TG Therapeutics common shares.

How many TG Therapeutics (TGTX) Stock Tracking Units does Daniel Hume hold after this grant?

After this transaction, Daniel Hume holds 8,325 Stock Tracking Units directly. These units each track the value of one TG Therapeutics common share and may settle in stock or cash after vesting.